AU2019267166C1 - Furin inhibitors - Google Patents

Furin inhibitors Download PDF

Info

Publication number
AU2019267166C1
AU2019267166C1 AU2019267166A AU2019267166A AU2019267166C1 AU 2019267166 C1 AU2019267166 C1 AU 2019267166C1 AU 2019267166 A AU2019267166 A AU 2019267166A AU 2019267166 A AU2019267166 A AU 2019267166A AU 2019267166 C1 AU2019267166 C1 AU 2019267166C1
Authority
AU
Australia
Prior art keywords
methyl
pyridin
oxy
dichlorophenyl
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019267166A
Other languages
English (en)
Other versions
AU2019267166A1 (en
AU2019267166B2 (en
Inventor
Jeffrey Michael Axten
Mui Cheung
Michael P. Demartino
Huiping Amy Guan
Yan Hu
Xiaojuan Lin
Aaron Bayne Miller
Donghui Qin
Chengde Wu
Zhiliu Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of AU2019267166A1 publication Critical patent/AU2019267166A1/en
Publication of AU2019267166B2 publication Critical patent/AU2019267166B2/en
Application granted granted Critical
Publication of AU2019267166C1 publication Critical patent/AU2019267166C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
AU2019267166A 2018-05-11 2019-05-10 Furin inhibitors Active AU2019267166C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862670050P 2018-05-11 2018-05-11
US62/670,050 2018-05-11
PCT/EP2019/062098 WO2019215341A1 (en) 2018-05-11 2019-05-10 Furin inhibitors

Publications (3)

Publication Number Publication Date
AU2019267166A1 AU2019267166A1 (en) 2020-11-26
AU2019267166B2 AU2019267166B2 (en) 2023-06-15
AU2019267166C1 true AU2019267166C1 (en) 2023-11-30

Family

ID=66597541

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019267166A Active AU2019267166C1 (en) 2018-05-11 2019-05-10 Furin inhibitors

Country Status (12)

Country Link
US (1) US11773078B2 (https=)
EP (1) EP3790871B1 (https=)
JP (1) JP7350061B2 (https=)
KR (1) KR102823187B1 (https=)
CN (1) CN112384509B (https=)
AU (1) AU2019267166C1 (https=)
BR (1) BR112020022961A2 (https=)
CA (1) CA3099863A1 (https=)
IL (2) IL278642B2 (https=)
MX (1) MX2020012034A (https=)
SG (1) SG11202010914YA (https=)
WO (1) WO2019215341A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112384509B (zh) 2018-05-11 2024-04-30 葛兰素史密斯克莱知识产权发展有限公司 弗林蛋白酶抑制剂
WO2021097008A1 (en) * 2019-11-12 2021-05-20 Bp Asset V, Inc. Use of pyridyloxypyridines for treating infectious diseases
CA3157892A1 (en) * 2019-11-12 2021-05-20 Keith Wilcoxen Small molecule furin inhibitors for treating infectious diseases
WO2021097002A1 (en) * 2019-11-12 2021-05-20 Bp Asset V, Inc. Use of pyridyloxypyrimidines for treating infectious diseases
JP2023521032A (ja) * 2020-04-02 2023-05-23 ビーピー アセット ヴイ，インコーポレーテッド コロナウイルス感染症を処置するためのフーリンインヒビター
FR3110345B1 (fr) 2020-05-21 2024-03-29 Agence Francaise Pour Le Dev D’Al Ula Hydrolysat de protéines du tourteau des graines de Moringa peregrina pour son application en tant que médicament, son procédé d’obtention et compositions pharmaceutiques, dermatologiques et cosmétiques.
CN117222410A (zh) * 2021-02-03 2023-12-12 Bp资产V股份有限公司 用于吸入的弗林蛋白酶抑制剂的制剂
CN114853640A (zh) * 2022-05-12 2022-08-05 马鞍山昂扬新材料科技有限公司 2-溴乙基磺酸钠的制备方法
WO2024073576A1 (en) * 2022-09-29 2024-04-04 Bp Asset V, Inc. 4-((2-(3,5-dichlorophenyl)-6-((pyrimidin-5-yl)oxy)pyridin-4-yl)methyl)piperazine derivatives as furin inhibitors and uses thereof
DE102023126563A1 (de) * 2023-09-28 2025-04-03 Philipps-Universität Marburg, Körperschaft des öffentlichen Rechts Hemmstoffe der Proproteinkonvertase Furin, Verfahren zu deren Herstellung und Verwendung
CN119119096B (zh) * 2024-09-09 2025-09-16 郑州药领医药科技有限公司 一种4-((4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)甲基)哌啶-1-甲酸叔丁酯的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016144702A1 (en) * 2015-03-06 2016-09-15 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1646160A (zh) 2002-03-13 2005-07-27 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
US7423148B2 (en) 2002-11-21 2008-09-09 Chiron Corporation Small molecule PI 3-kinase inhibitors and methods of their use
WO2005047268A2 (en) 2003-11-10 2005-05-26 X-Ceptor Therapeutics, Inc. Substituted pyrimidine compositions and methods of use
CA2586086A1 (en) 2004-07-23 2006-01-23 Robert E.(Deceased) Smith Furin inhibitors
EP1789413A1 (en) * 2004-09-13 2007-05-30 Amgen Inc. Vanilloid receptor ligands and their use in treatments
EP2155894A4 (en) 2007-05-09 2010-08-18 Burnham Inst Medical Research HOST PROTEINAS AS A TARGET FOR A THERAPEUTIC STRATEGY AGAINST VIRAL AND BACTERIAL DISEASES
MX2010008700A (es) 2008-02-22 2010-08-30 Hoffmann La Roche Moduladores de beta-amiloide.
CN107011359A (zh) 2010-10-18 2017-08-04 塞伦尼斯医疗控股有限公司 可用于胆固醇动员的化合物、组合物和方法
WO2013138666A1 (en) 2012-03-16 2013-09-19 Sanford-Burnham Medical Research Institute Inhibitors of furin and other pro-protein convertases
US9266828B2 (en) 2012-03-16 2016-02-23 Sanford-Burnham Medical Research Institute Inhibitors of Furin and other pro-protein convertases
EP2884982B1 (en) * 2012-08-20 2017-09-20 Merck Sharp & Dohme Corp. SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
WO2014152716A1 (en) 2013-03-15 2014-09-25 President And Fellows Of Harvard College Substituted heterocyclic compounds for treating or preventing viral infections
CN107441094B (zh) 2017-08-08 2020-05-22 南方医科大学 尼罗替尼作为治疗登革病毒感染的药物及其制药用途
CN112384509B (zh) 2018-05-11 2024-04-30 葛兰素史密斯克莱知识产权发展有限公司 弗林蛋白酶抑制剂
CA3157892A1 (en) 2019-11-12 2021-05-20 Keith Wilcoxen Small molecule furin inhibitors for treating infectious diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016144702A1 (en) * 2015-03-06 2016-09-15 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof

Also Published As

Publication number Publication date
AU2019267166A1 (en) 2020-11-26
IL302997B1 (en) 2024-04-01
IL278642B2 (en) 2023-10-01
IL302997A (en) 2023-07-01
IL278642A (https=) 2020-12-31
IL278642B1 (en) 2023-06-01
BR112020022961A2 (pt) 2021-02-17
KR102823187B1 (ko) 2025-06-20
KR20210021298A (ko) 2021-02-25
CA3099863A1 (en) 2019-11-14
EP3790871A1 (en) 2021-03-17
EP3790871C0 (en) 2024-01-24
CN112384509A (zh) 2021-02-19
US11773078B2 (en) 2023-10-03
CN112384509B (zh) 2024-04-30
EP3790871B1 (en) 2024-01-24
MX2020012034A (es) 2021-04-12
SG11202010914YA (en) 2020-12-30
JP7350061B2 (ja) 2023-10-02
JP2021523941A (ja) 2021-09-09
AU2019267166B2 (en) 2023-06-15
WO2019215341A1 (en) 2019-11-14
US20220315556A1 (en) 2022-10-06
IL302997B2 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
AU2019267166C1 (en) Furin inhibitors
AU2019360928B2 (en) Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
JP7286317B2 (ja) Ａｃｉｎｅｔｏｂａｃｔｅｒ ｂａｕｍａｎｎｉｉに対するペプチド大環状分子
JP7035055B2 (ja) Ｎ－（ピリジン－２－イル）ピリジン－スルホンアミド誘導体および疾患の処置におけるそれらの使用
KR20210152515A (ko) 이카로스 및 아이올로스의 트리시클릭 분해제
CN114144230B (zh) 作为eed和prc2调节剂的大环唑并吡啶衍生物
CA2853975A1 (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity
EP4182308B1 (en) Pyridazinyl amino derivatives as alk5 inhibitors
AU2020250185A1 (en) Pyridine carbonyl derivatives and therapeutic uses thereof as TRPC6 inhibitors
EP3283475A1 (en) 3-(1h-benzimidazol-2-yl)-1h-pyridin-2-one derivatives
WO2023006013A1 (zh) 新型parp7抑制剂及其应用
AU2017372377B2 (en) Imidazo [1,5-a] pyrazine derivatives as PI3Kdelta inhibitors
WO2022040259A1 (en) Imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine derivatives as tlr9 inhibitors for the treatment of fibrosis
RU2799824C2 (ru) Ингибиторы фурина
EP3256132A1 (en) Pyrimidine derivatives for use in the treatment of cancer
HK40047035A (en) Furin inhibitors
HK40047035B (en) Furin inhibitors
IL303227B2 (en) Combined pumped storage power plant - desalination plant on the beach (ocean), or river, or lake
US20230365531A1 (en) Inhibitors of human respiratory syncytial virus and metapneumo virus
CN117412959A (zh) 经取代的1-芳基-1'-杂芳基化合物、经取代的1,1'-联杂芳基化合物和其使用方法
EA050655B1 (ru) Замещенные бициклические соединения, пригодные для применения в качестве ингибиторов tlr9
HK40075584A (en) Kv3 enhancers for the treatment of cognitive disorders
HK1201265B (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity
HK1241873A1 (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity
HK1241873B (zh) 作为btk活性的抑制剂的杂芳基吡啶酮和氮杂-吡啶酮化合物

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 05 JUN 2023

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 05 JUN 2023

FGA Letters patent sealed or granted (standard patent)